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Summary and conclusions.
Since the introduct ion ofthe immunosuppressive drug cic losporin A (CsA), the results
of virtually all organ transplant programs have shown a tremendous improvement, as
illustrated by, a prolonged graft survival, a marked reduction of serious rejection
episodes, and a reduct ion in the number of long term steroid- induced compl icat ions.
Nevertheless, these improvements have been realized at the expense of newly
introduced, CsA-induced side effects. Of which the most important is its nephrotoxicity.
The nephrotoxic effect of CsA is not due to excessive dose regimens, but can be
observed well within the therapeutÍc range of this drug. lt has also been established
that there is a strong individual sensitivity with regard to this nephrotoxic efíect of CsA.
Despite this complication, the use of this drug holds ample advantages in favor oí
former immunosuppressive regimens. Thus, the use oí CsA has now been wel l -
establ ished as a corner stone oÍ the immunosuppressive protocol in most renal
transplant programs.
Therefore, a lot of energy has been devoted to research, aimed at elucrdating the
mechanisms oÍ CsA nephrotoxicity and at developing strategies to mrnimize this
serious l imitat ion of the therapeut ic window of this drug.
It has now been established that a reduced renal blood Ílow is the prrmary
pathogenetic event in CsA nephrotoxicity. CsA has been shown to disturb the balance
between the vasoconstrictor and the vasodilator eicosanoids, which are involved in the
regulat ion oÍ renal blood Í low, and as such in the overal l  períormance of the kidney.
Following the recognition oÍ the CsA-induced shíft owards vasoconstrictor eicosanoids,
studies aimed at restor ing, or intervening in,  the CsA-induced changes in eicosanoid
metabolism have been undertaken.
Since eicosanoids, and amongst them prostaglandins, are synthesized Írom
polyunsaturated fatty acids (PUFA), of which, in physiological conditions, arachidonic
acid predominates, there seems to be a role for dietary interventions with several other
PUFA's to aÍfect renal íunction in CsA-treated oatients.
An increasing interest in the use oÍ f ish oi l ,  mainly const i tut ing ofEPA (C20:5 g-3) and
DHA (C22:64-3), has recently arisen. This interest has started with the reports on a
reduced incidence of cardiovascular disease in Greenland eskimo's.  Extensive
research on this matter revealed that a diet consisting oÍ a high intake oÍ fish, and
more precise a high intake of EPA and DHA could be held responsible for this
phenomenon. Although the mechanisms by which Í ish oi l  reduces the r isk for
cardiovascular disease have not been completely elucidated, a number of potential
mechanisms have now been proposed. Firstly, a beneíicial effect on blood lipids has
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been reported under various conditions; a lowering of triglycerides has been
undisputedly reported, while in some but not all, studies a slight decrease in total
cholesterol or a decrease in the HDULDL has been reported. Secondly, analogous to
arachidonic acid, EPA can Íunction as precursor íor the eicosanoid metabolism.
However, the EPA-deríved eicosanoids have a different physiological ctivity, being
less platelet aggretory and more vasodilatory. lt has also been shown that the dietary
use of EPA results in a decrease of the erythrocyte deíormability and leads to a
decrease of the blood viscosity.
All these properties of EPA can contribute to a decreased incidence oÍ cardiovascular
disease. Patients with end stage renal disease often have increased blood lipid levels
which contribute to an increased risk for cardiovascular disease in this group of
patients. This, in combination with the efÍects on eicosanoid synthesis, which apart
from their eífect on renal Íunction might also contribute to the immune modulatory
effects oÍ Íish oil, has been the justification íor the hypothesis that both renal function
and the risk íor cardíovascular disease could possibly benefit from dietary interventions
with Íish oil in CsA-treated renal transplant recipients. Indeed, in experimental
conditions this has been observed; thereÍore, it seemed íit to investigate the eÍfects
of dietary fish oil in CsA-treated renal transplant recipients.
This thesis presents the results and the perspective oí a number oÍ these clinical
studies. Chapter one consists of a brief introduction and describes the aims of the
studies. In chapter two the nephrotoxic properties, the pathophysiology and the clinical
management oÍ the drug CsA are reviewed, explaining the rationale and the clinical
setting for a dietary intervention with fish oil.
Chapter three deals with the eÍÍects of dietary fish oil in various conditions oÍ chronic
renal insufíiciency.
Chapter four deals with the short term eÍÍects oÍ 6 g fish oil in a relative small group
oÍ renal transplant recipients with stable renal function and on cyclosporin Íor at least
a year. In this group oí patients, the addition of íish oil to their diet resulted in an
increase oÍ the GFR and the ËRPF of + 18%, whi le blood pressure decreased
significantly with approximately 10 mmHg. These promising results raised several
questions such as whether the increase in renal function can be considered as
beneficial on the long term. lt has, for inslance, been demonstrated that the induction
of so called "hyperÍiltration" as measured by a loss in renal reserve Íiltration capacity,
might be detrimental on the long term.
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This matter is addressed in chapter five. in which it is shown that the addition of Íish
oil did not resull in a loss of renal reserve Íiltration capacity. On the contrary the fish
oil and CsA{reated patients had a higher renal reserye filtration capacity than the
placebo and CsA-treated patients. These observations lead to the conclusion that a
long term detrimental effect of dietary fish oil seemed unlikely. From the data
presented in chapter six it is concluded that dietary Íish oil has profound efÍects on the
course of the renal function during the recovery phase Íollowing an early postoperative
acute rejection episode of the renal allograft. Although per rejection episode no
dif ference in the amount of addit ional immune suppression administered could be
observed, the response oÍ the renal function on the anti-rejection therapy was
signiÍicantly better and Íaster in the fish oil{reated patients. From these data, however,
we were not able to conclude whether the beneÍicial effects of Íish oil during an acute
cel lular eject ion episode were due to pr imary- immunological ly or hemodynamical ly
induced changes.
Chapter seven deals with a study with a one year follow up. In this chapter it is
demonstrated that the Íish oil{reated patients had a lower blood pressure and a lower
calculated renal vascular esistance as wel l  as a hrgher GFR, ERPF and FF at one
year after grafting. Remarkable was the observed low incidence of acute rejection
episodes in the fish oil-treated patients (23%) compared to the placebo oil{reated
patients (64Vo). This clinical observation is supported by in vivo and in vitro
observations on the efÍects of dietary fishoil on the immune system as well as by
transplantation experiments, which are all reviewed in chapter eight.
As mentioned above, patients with renal disease, and especially those receiving a
renal allograft have an increased risk for the development of cardiovascular disease,
this is at least partially due to the presence of a number oÍ well-known risk Íactors, as
also reviewed in chapter eight. Although in this thesis it can not be demonstrated that
dietary supplements with fish oil reduce the risk rate for cardiovascular disease in this
particular group of patients, indeed there are some data presented that aÍfect some
specific risk Íactors. A lower blood pressure has been observed in nearly all CsA and
fish oil-treated patients compared to the control groups, as also was presented in the
chapters four and seven.
Parts oÍ chapter 3 and 8 present data on the blood lipid profile before and after fish
oil administration. From these data it can be concluded that triglycerides are reduced
by 30%, The decrease in blood pressure and blood lipids may possibly contribute to
a future decrease in the incidence of cardiovascular disease on the lonq term after
prolonged lreatment with Í ish oi l .
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In al l  of  the above mentioned cl inical  t r ia ls we did not observe any ser ious ide effects
associated with the f ish oi l  supplementat ion, especial ly hemostat ic disorders were not
reported in our studies.
In summary, we observed a better renal íunct ion, a lower blood pressure, a better
response oÍ renal Íunction to anti-rejection therapy, and, after prolonged treatment a
reduced incidence of acute cel lular reject ion after a dietary supplementat ion with f ish
oil in CsA-treated renaltransplant recipients. In addition, blood lipÍd proÍile was altered
in a predominant Íavorable manner, while no detrimental effects attributable to fish oil
ingestion were observed.
Therefore, it can be stated, that despite the necessity Íor extension, validation and
further insight in the mechanisms involved, a dietary supplement oí six grams
containing 50% O-3 poly unsaturated fatty acids is a useÍul and safe adjuvant therapy
for CsA-treated renal transplant recipients.
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